Vanguard Capital Management’s Grace Therapeutics GRCE Stock Holding History
Bought
Maintained
Sold
Other funds holding GRCE
OM
Vanguard Capital Management's GRCE Position: Q3 2026 in Review
Vanguard Capital Management reduced its Grace Therapeutics (GRCE) stake by 2.8% in Q3 2026, selling an estimated $25.2K and leaving 400,350 shares worth $861K. The position accounts for ﹤0.01% of the portfolio, ranked #3599.
Vanguard Capital Management first reported a position in GRCE in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.86M in Q1 2026. 38 funds tracked by Wall St. Rank hold GRCE as of Q3 2026.
- Vanguard Capital Management held 400,350 shares of Grace Therapeutics worth $861K as of Q3 2026.
- Vanguard Capital Management sold 11,364 Grace Therapeutics shares in Q3 2026, an estimated $25.2K.
- Grace Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3599 holding.
- Vanguard Capital Management first reported a position in Grace Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Grace Therapeutics position peaked at $1.86M in Q1 2026.
- 38 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.